



An Oral Available STING Antagonist for the treatment of Autoimmune Syndromes


Ya-Hui Chi, Shau-Hua Ueng

Institute of Biotechnology and Pharmaceutical Research National Health Research Institutes

Oral STING inhibitor

Features of IBPR Oral Sting Inhibitors

- Patent enable
- Highly bioavailable *via* oral, intravenous or subcutaneous administration
- More than 20-fold increased potency compare to H-151 in human cells
- Demonstrated *in vivo* efficacy in ameliorating inflammation in the heart and lung of the *Trex1*^{-/-} autoimmune mouse model *via* oral administration
- Potential disease indications: chronic autoimmune syndromes, enhanced type-I interferon responses during acute inflammation, neuroinflammatory diseases, chronic bowel disease, chronic kidney disease



cGAS-STING related human diseases

Brian

- Interferonopathies
- Neurodegenerative diseases

Eye

- Macular degeneration

Lung

- SAVI
- COPA syndrome
- COVID-19

Heart

- Infarction
- Cardiomyopathy

Liver

- NAFLD
- NASH

Kidney

- AKI
- Fibrosis ?

Intestine

- Microbiome
- IBD

Skin

- Microbiome
- Chilblain lupus
- Acne
- COVID-19

Systemic disease processes

- Autoinflammation and autoimmunity
- Ageing
- Cancer (agonist)

Ref: Nat Rev Nephrol 18 (2022) 558–572.

Created with BioRender.com